Polypharmacy and potentially inappropriate medicine use in older adults with cancer: a multicenter cross-sectional study in Northwest Ethiopia oncologic centers.

IF 3.3 Q1 HEALTH POLICY & SERVICES Journal of Pharmaceutical Policy and Practice Pub Date : 2024-10-01 eCollection Date: 2024-01-01 DOI:10.1080/20523211.2024.2397797
Samuel Agegnew Wondm, Tilaye Arega Moges, Samuel Berihun Dagnew, Fisseha Nigussie Dagnew, Tirsit Ketsela Zeleke, Rahel Belete Abebe, Endalamaw Aschale Mihrete, Fasil Bayafers Tamene
{"title":"Polypharmacy and potentially inappropriate medicine use in older adults with cancer: a multicenter cross-sectional study in Northwest Ethiopia oncologic centers.","authors":"Samuel Agegnew Wondm, Tilaye Arega Moges, Samuel Berihun Dagnew, Fisseha Nigussie Dagnew, Tirsit Ketsela Zeleke, Rahel Belete Abebe, Endalamaw Aschale Mihrete, Fasil Bayafers Tamene","doi":"10.1080/20523211.2024.2397797","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most patients with cancer have comorbid conditions that necessitate advanced medical treatment. Polypharmacy (PP) and potentially inappropriate medicine (PIM) use is common among older adult patients with cancer. Not much research has been conducted on PP and PIM use among older adult patients with cancer in Ethiopian oncology centers. Therefore, this study aimed to evaluate the prevalence and determinants of PP and PIM use among older adults with cancer in Northwest Ethiopia oncology centers using the American Geriatrics Society (AGS) 2019 updated Beers criteria.</p><p><strong>Methods: </strong>This multicenter cross-sectional study was conducted among older adult patients with cancer from July 15-December 30, 2023 in Northwest Ethiopian oncology centers. The use of at least one drug included in the 2019 Beers criteria revisions was classified as potentially inappropriate medication use. To identify the factors influencing PP and PIM use, logistic regression analysis was performed.</p><p><strong>Results: </strong>Of the 310 samples aproched, 305(98.4% response rate) participated in the study. The prevalence of PP and PIM use were 70.2% (95% CI 64.9-75.1) and 63.0% (95% CI 57.4-68.8) respectively. Being female AOR:3.6; 95% CI:1.7-7.8; p =  0. 001, advanced age [(70-74 years) AOR:3.9; 95% CI:1.2-6.7; p =  0.046 and ≥75 years AOR:3.8; 95% CI:1.7-8.4; p =  0.0028], abnormal body weight (underweight AOR:5.5; 95% CI:1.5-9.6; p =  0.019, overweight AOR:5.1; 95% CI:1.5-7.3; p = 0.01 and obese AOR:5.6; 95% CI:1.5-9.3; p = 0.021) and comorbidities AOR:3.5; 95% CI:1.7-8.3; p =  0.0032 were statistically significant factors for PP. Advanced age [(70-74 years) AOR:5.5; 95% CI:1.4-9.8; p =  0.015 and ≥75 years AOR:3.3; 95% CI:1.5-7.1; p = 0.002)] and polypharmacy; AOR:7; 95% CI:3.4-9.4; p = 0.001 were statistically significant factors for PIM use.</p><p><strong>Conclusion: </strong>Polypharmacy and potentially inappropriate medicine use were prevalent among older adult patients with cancer. Ensuring safe medicines prescription practices for older patients with cancer requires understanding the issue, stopping unwarranted treatment, and replacing it with less toxic, age-appropriate medicines.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445903/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2024.2397797","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Most patients with cancer have comorbid conditions that necessitate advanced medical treatment. Polypharmacy (PP) and potentially inappropriate medicine (PIM) use is common among older adult patients with cancer. Not much research has been conducted on PP and PIM use among older adult patients with cancer in Ethiopian oncology centers. Therefore, this study aimed to evaluate the prevalence and determinants of PP and PIM use among older adults with cancer in Northwest Ethiopia oncology centers using the American Geriatrics Society (AGS) 2019 updated Beers criteria.

Methods: This multicenter cross-sectional study was conducted among older adult patients with cancer from July 15-December 30, 2023 in Northwest Ethiopian oncology centers. The use of at least one drug included in the 2019 Beers criteria revisions was classified as potentially inappropriate medication use. To identify the factors influencing PP and PIM use, logistic regression analysis was performed.

Results: Of the 310 samples aproched, 305(98.4% response rate) participated in the study. The prevalence of PP and PIM use were 70.2% (95% CI 64.9-75.1) and 63.0% (95% CI 57.4-68.8) respectively. Being female AOR:3.6; 95% CI:1.7-7.8; p =  0. 001, advanced age [(70-74 years) AOR:3.9; 95% CI:1.2-6.7; p =  0.046 and ≥75 years AOR:3.8; 95% CI:1.7-8.4; p =  0.0028], abnormal body weight (underweight AOR:5.5; 95% CI:1.5-9.6; p =  0.019, overweight AOR:5.1; 95% CI:1.5-7.3; p = 0.01 and obese AOR:5.6; 95% CI:1.5-9.3; p = 0.021) and comorbidities AOR:3.5; 95% CI:1.7-8.3; p =  0.0032 were statistically significant factors for PP. Advanced age [(70-74 years) AOR:5.5; 95% CI:1.4-9.8; p =  0.015 and ≥75 years AOR:3.3; 95% CI:1.5-7.1; p = 0.002)] and polypharmacy; AOR:7; 95% CI:3.4-9.4; p = 0.001 were statistically significant factors for PIM use.

Conclusion: Polypharmacy and potentially inappropriate medicine use were prevalent among older adult patients with cancer. Ensuring safe medicines prescription practices for older patients with cancer requires understanding the issue, stopping unwarranted treatment, and replacing it with less toxic, age-appropriate medicines.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
埃塞俄比亚西北部肿瘤中心的一项多中心横断面研究:老年癌症患者的多重用药和潜在的不当用药。
背景:大多数癌症患者都患有需要接受晚期治疗的并发症。多药(PP)和潜在不当用药(PIM)在老年癌症患者中很常见。埃塞俄比亚肿瘤中心对老年癌症患者使用多种药物和潜在不适当药物的研究不多。因此,本研究旨在采用美国老年医学会(AGS)2019 年更新的 Beers 标准,评估埃塞俄比亚西北部肿瘤中心的老年癌症患者使用 PP 和 PIM 的流行率和决定因素:这项多中心横断面研究于 2023 年 7 月 15 日至 12 月 30 日在埃塞俄比亚西北部肿瘤中心的老年癌症患者中进行。至少使用一种2019年Beers标准修订版中包含的药物被归类为潜在用药不当。为确定影响 PP 和 PIM 使用的因素,进行了逻辑回归分析:在调查的 310 个样本中,有 305 个样本(回复率为 98.4%)参与了研究。PP 和 PIM 的使用率分别为 70.2% (95% CI 64.9-75.1) 和 63.0% (95% CI 57.4-68.8)。女性 AOR:3.6; 95% CI:1.7-7.8; p = 0. 001,高龄[(70-74 岁)AOR:3.9; 95% CI:1.2-6.7; p = 0.046 和≥75 岁 AOR:3.8; 95% CI:1.7-8.4; p = 0.0028],体重异常(体重不足 AOR:5.5; 95% CI:1.5-9.6; p = 0.019,超重 AOR:5.1; 95% CI:1.5-7.3; p = 0.01 和肥胖 AOR:5.6; 95% CI:1.5-9.3; p = 0.021)和合并症 AOR:3.5; 95% CI:1.7-8.3; p = 0.0032 是 PP 的显著统计学因素。高龄[(70-74 岁)AOR:5.5; 95% CI:1.4-9.8; p = 0.015 和≥75 岁 AOR:3.3; 95% CI:1.5-7.1; p = 0.002)]和多药; AOR:7; 95% CI:3.4-9.4; p = 0.001 是使用 PIM 的统计学显著因素:结论:在老年癌症患者中,多药和潜在的用药不当现象十分普遍。要确保老年癌症患者的处方用药安全,就必须了解这一问题,停止不必要的治疗,并用毒性较低、适合年龄的药物取而代之。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice Health Professions-Pharmacy
CiteScore
4.70
自引率
9.50%
发文量
81
审稿时长
14 weeks
期刊最新文献
A quantitative investigation in a territory of Italy on citizens' attitudes towards medicines through the COVID-19 pandemic: the importance of possible indirect effects caused by the pandemic. Cost-effectiveness analysis of genotype-guided optimization of major depression treatment in Qatar. Exploring the influencing factors of adverse drug reaction reporting among medical personnel: a COM-B model-based study. Pharmacovigilance: the evolution of drug safety monitoring. Inhaler personalisation based on peak inspiratory flow (PIF) among dry powder inhaler users: a pilot randomised control trial (RCT) in COPD.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1